| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|
J Clin Oncol
|
2005
|
8.87
|
|
2
|
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
|
Cancer Res
|
2008
|
8.12
|
|
3
|
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
|
Lancet Oncol
|
2011
|
7.10
|
|
4
|
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
|
Lancet
|
2010
|
5.79
|
|
5
|
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
|
Cancer Res
|
2009
|
5.68
|
|
6
|
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
|
Cancer Cell
|
2009
|
4.71
|
|
7
|
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
|
JAMA
|
2011
|
4.63
|
|
8
|
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
|
J Natl Cancer Inst
|
2008
|
3.60
|
|
9
|
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
|
Breast Cancer Res
|
2010
|
3.53
|
|
10
|
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
3.07
|
|
11
|
Adjuvant docetaxel for high-risk, node-negative breast cancer.
|
N Engl J Med
|
2010
|
2.99
|
|
12
|
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
|
J Clin Oncol
|
2005
|
2.54
|
|
13
|
Progress against solid tumors in danger: the metastatic breast cancer example.
|
J Clin Oncol
|
2012
|
2.05
|
|
14
|
Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
|
Expert Rev Pharmacoecon Outcomes Res
|
2014
|
1.99
|
|
15
|
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
|
Cancer Treat Rev
|
2011
|
1.98
|
|
16
|
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
|
J Clin Oncol
|
2007
|
1.93
|
|
17
|
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
|
Clin Cancer Res
|
2010
|
1.81
|
|
18
|
Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
|
Cancer Treat Rev
|
2010
|
1.79
|
|
19
|
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
|
Clin Cancer Res
|
2006
|
1.70
|
|
20
|
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
|
J Clin Oncol
|
2009
|
1.68
|
|
21
|
NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer.
|
Clin Cancer Res
|
2002
|
1.57
|
|
22
|
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.
|
Breast Cancer Res Treat
|
2010
|
1.50
|
|
23
|
Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.
|
Clin Cancer Res
|
2009
|
1.43
|
|
24
|
[Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project].
|
Med Clin (Barc)
|
2004
|
1.41
|
|
25
|
Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer.
|
Cancer Res
|
2007
|
1.34
|
|
26
|
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
|
J Clin Oncol
|
2009
|
1.33
|
|
27
|
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer.
|
Clin Proteomics
|
2011
|
1.32
|
|
28
|
Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates.
|
Med Oral Patol Oral Cir Bucal
|
2007
|
1.29
|
|
29
|
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.
|
Breast Cancer Res Treat
|
2008
|
1.25
|
|
30
|
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer.
|
J Clin Oncol
|
2010
|
1.10
|
|
31
|
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
|
J Clin Oncol
|
2013
|
1.05
|
|
32
|
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer.
|
Breast Cancer Res
|
2012
|
1.01
|
|
33
|
High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients.
|
Oncologist
|
2012
|
0.99
|
|
34
|
The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population.
|
Breast Cancer Res Treat
|
2012
|
0.99
|
|
35
|
High stability of microRNAs in tissue samples of compromised quality.
|
Virchows Arch
|
2013
|
0.98
|
|
36
|
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).
|
Breast Cancer Res Treat
|
2011
|
0.97
|
|
37
|
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo Register.
|
Breast Cancer Res Treat
|
2010
|
0.97
|
|
38
|
Genetic polymorphisms in DNA repair and oxidative stress pathways associated with malignant melanoma susceptibility.
|
Eur J Cancer
|
2011
|
0.96
|
|
39
|
Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population.
|
BMC Cancer
|
2013
|
0.95
|
|
40
|
MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis.
|
Eur J Cancer
|
2012
|
0.95
|
|
41
|
Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.
|
Breast Cancer Res Treat
|
2009
|
0.93
|
|
42
|
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
|
Breast Cancer Res
|
2013
|
0.93
|
|
43
|
Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer.
|
Clin Cancer Res
|
2002
|
0.92
|
|
44
|
Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.
|
Cancer Treat Rev
|
2008
|
0.92
|
|
45
|
Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.
|
PLoS One
|
2013
|
0.90
|
|
46
|
Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study.
|
Clin Cancer Res
|
2009
|
0.89
|
|
47
|
A customized pigmentation SNP array identifies a novel SNP associated with melanoma predisposition in the SLC45A2 gene.
|
PLoS One
|
2011
|
0.88
|
|
48
|
MicroRNAs in Breast Cancer: One More Turn in Regulation.
|
Curr Drug Targets
|
2016
|
0.87
|
|
49
|
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
|
Oncologist
|
2012
|
0.87
|
|
50
|
Trastuzumab in small tumours and in elderly women.
|
Cancer Treat Rev
|
2013
|
0.87
|
|
51
|
Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity.
|
J Acad Nutr Diet
|
2016
|
0.85
|
|
52
|
MicroRNA profile in very young women with breast cancer.
|
BMC Cancer
|
2014
|
0.85
|
|
53
|
Nitration of cathepsin D enhances its proteolytic activity during mammary gland remodelling after lactation.
|
Biochem J
|
2009
|
0.84
|
|
54
|
Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
|
Melanoma Res
|
2009
|
0.84
|
|
55
|
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.
|
BMC Cancer
|
2014
|
0.83
|
|
56
|
Current perspectives of treatment of ductal carcinoma in situ.
|
Cancer Treat Rev
|
2010
|
0.83
|
|
57
|
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
|
Cancer
|
2005
|
0.83
|
|
58
|
Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?
|
Breast
|
2011
|
0.82
|
|
59
|
Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials.
|
Cancer Treat Rev
|
2007
|
0.81
|
|
60
|
Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
|
Clin Transl Oncol
|
2009
|
0.80
|
|
61
|
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
|
Expert Rev Pharmacoecon Outcomes Res
|
2013
|
0.80
|
|
62
|
An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.
|
Breast
|
2013
|
0.79
|
|
63
|
Oxidative stress in susceptibility to breast cancer: study in Spanish population.
|
BMC Cancer
|
2014
|
0.79
|
|
64
|
Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.
|
Oncologist
|
2011
|
0.79
|
|
65
|
Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.
|
Mol Cell Biochem
|
2013
|
0.78
|
|
66
|
Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
|
Cancer Treat Rev
|
2005
|
0.78
|
|
67
|
Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain).
|
Clin Transl Oncol
|
2008
|
0.77
|
|
68
|
rs12512631 on the group specific complement (vitamin D-binding protein GC) implicated in melanoma susceptibility.
|
PLoS One
|
2013
|
0.77
|
|
69
|
Supportive care for patients with early breast cancer.
|
Clin Transl Oncol
|
2010
|
0.77
|
|
70
|
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.
|
Oncologist
|
2016
|
0.76
|
|
71
|
A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer.
|
Clin Breast Cancer
|
2003
|
0.76
|
|
72
|
Evolution of tumour biology upon progression. Do we know our enemy?
|
Clin Transl Oncol
|
2012
|
0.75
|
|
73
|
Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients.
|
Int J Mol Sci
|
2012
|
0.75
|
|
74
|
In response: Genomic profile of breast cancer.
|
Expert Rev Pharmacoecon Outcomes Res
|
2015
|
0.75
|
|
75
|
Outcome differences between patients with node-negative breast cancer classified according to the st. Gallen risk categories.
|
Clin Breast Cancer
|
2009
|
0.75
|
|
76
|
[Neoadjuvant therapy for operable breast-cancer].
|
Med Clin (Barc)
|
2006
|
0.75
|
|
77
|
The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II/III trials.
|
Clin Breast Cancer
|
2007
|
0.75
|
|
78
|
Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.
|
Anticancer Res
|
2010
|
0.75
|
|
79
|
Time-to-progression in breast cancer: a stratification model for clinical trials.
|
Breast
|
2007
|
0.75
|
|
80
|
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
|
Curr Cancer Drug Targets
|
2016
|
0.75
|
|
81
|
Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.
|
Clin Transl Oncol
|
2008
|
0.75
|